Human iPSC‐Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System
Small · 2023
DOI: 10.1002/smll.202203725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Lin Qi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Science and Toxicology, College of Natural Resources, University of California Berkeley, Berkeley, CA, 94720, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, Gordon and Betty Moore Foundation.
Abstract (Originalsprache)
Chronic white adipose tissue (WAT) inflammation has been recognized as a critical early event in the pathogenesis of obesity‐related disorders. This process is characterized by the increased residency of proinflammatory M1 macrophages in WAT. However, the lack of an isogenic human macrophage‐adipocyte model has limited biological studies and drug discovery efforts, highlighting the need for human stem cell‐based approaches. Here, human induced pluripotent stem cell (iPSC) derived macrophages (iMACs) and adipocytes (iADIPOs) are cocultured in a microphysiological system (MPS). iMACs migrate toward and infiltrate into the 3D iADIPOs cluster to form crown‐like structures (CLSs)‐like morphology around damaged iADIPOs, recreating classic histological features of WAT inflammation seen in obesity. Significantly more CLS‐like morphologies formed in aged and palmitic acid‐treated iMAC‐iADIPO‐MPS, showing the ability to mimic inflammatory severity. Importantly, M1 (proinflammatory) but not M2 (tissue repair) iMACs induced insulin resistance and dysregulated lipolysis in iADIPOs. Both RNAseq and cytokines analyses revealed a reciprocal proinflammatory loop in the interactions of M1 iMACs and iADIPOs. This iMAC‐iADIPO‐MPS thus successfully recreates pathological conditions of chronically inflamed human WAT, opening a door to study the dynamic inflammatory progression and identify clinically relevant therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nutritional Science and Toxicology, College of Natural Resources, University of California Berkeley, Berkeley, CA, 94720, USA.
- Division of Endocrinology and Metabolism, Institute for Human Genetics, the Eli and Edythe Broad Institute for Regeneration Medicine, and the Program in Craniofacial Biology, Department of Medicine, University of Califo…
- Division of Transplant Surgery, Department of Surgery, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Liver Center, University of California, San Francisco, CA, 94143, USA.
ORCID-Profile: Lin Qi, Edward C Hsiao, Andreas Stahl
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- Gordon and Betty Moore Foundation
- Siebel Stem Cell Institute
Zitieren
APA
Qi, L., Matsuo, K., Pereira, A., Lee, Y. T., Zhong, F., He, Y., Zushin, P. H., Gröger, M., Sharma, A., Willenbring, H., Hsiao, E. C., & Stahl, A. (2023). Human iPSC‐Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System. Small. https://doi.org/10.1002/smll.202203725
Vancouver
Qi L, Matsuo K, Pereira A, Lee YT, Zhong F, He Y, et al. Human iPSC‐Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System. Small. 2023. doi:10.1002/smll.202203725
BibTeX
@article{Qi2023,
author = {Qi, Lin and Matsuo, Koji and Pereira, Ashley and Lee, Yue Tung and Zhong, Fenmiao and He, Yuchen and Zushin, Peter-James H and Gröger, Marko and Sharma, Aditi and Willenbring, Holger and Hsiao, Edward C and Stahl, Andreas},
title = {Human iPSC‐Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202203725}
}
EUVIMED